Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.
Liu B, Xie N, Tian C, Feng R, Hu ZY, Li J, Liu L, Xiao H, Yang X, Zeng M, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Tang Y, Wu T, Ouyang Q. Liu B, et al. Among authors: xie n. Breast. 2023 Dec;72:103597. doi: 10.1016/j.breast.2023.103597. Epub 2023 Nov 1. Breast. 2023. PMID: 37944341 Free PMC article.
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
Hu ZY, Yan M, Xiong H, Ran L, Zhong J, Luo T, Sun T, Xie N, Liu L, Yang X, Xiao H, Li J, Liu B, Ouyang Q. Hu ZY, et al. Among authors: xie n. BMC Med. 2023 Jun 26;21(1):226. doi: 10.1186/s12916-023-02943-2. BMC Med. 2023. PMID: 37365596 Free PMC article. Clinical Trial.
Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.
Shao X, Xie N, Chen Z, Wang X, Cao W, Zheng Y, Yang H, Huang J, Chen S, Gan L, Yang X, Chen Y, Ouyang Q, Wang X. Shao X, et al. Among authors: xie n. J Transl Int Med. 2024 Nov 6;12(5):466-477. doi: 10.1515/jtim-2024-0022. eCollection 2024 Nov. J Transl Int Med. 2024. PMID: 39513033 Free PMC article.
Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28).
Chen Y, Xie Y, Sang D, Xie N, Han X, Zhao Y, Li J, Yue J, Yuan P, Wang B. Chen Y, et al. Among authors: xie y, xie n. Ther Adv Med Oncol. 2024 Dec 17;16:17588359241302018. doi: 10.1177/17588359241302018. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39697620 Free PMC article.
1,476 results